Nabumetone
Product Images NDC 45865-464

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Nabumetone (NDC 45865-464). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (464 60)

Nabumetone Tablets 500mg generic for Relafen, labeled by Medsource Pharmaceuticals. The white oval tablets come in a unit dose bliste strip of 60 tablets. The label contains dosage information, warnings about dizziness and drowsiness, and instructions to avoid alcohol and take with food. The label is bilingual in English and Spanish.*

FDA Label Image

6mna (6mna)

Chemical structure of 6-methoxy-2-naphthylacetic acid (6MNA), the active metabolite of Nabumetone, as labeled in the image.*

FDA Label Image

Call (Call)

A text panel listing various symptoms and signs, including nausea, tiredness, itching, yellowing of skin or eyes, stomach pain, flu-like symptoms, blood vomiting, bloody or tarry bowel movements, unusual weight gain, skin rash or blisters with fever, and swelling of extremities. The content appears to detail potential adverse reactions or warnings.*

FDA Label Image

Gethelp (Gethelp)

A text panel listing symptoms including shortness of breath or trouble breathing, chest pain, weakness on one side of the body, slurred speech, and swelling of the face or throat. The text is organized in two columns within bordered boxes.*

FDA Label Image

Graph1 (Graph1)

A line chart depicting Nabumetone active metabolite (6MNA) plasma concentrations at steady state over time following once-daily dosing of 1000 mg and 2000 mg. The y-axis shows concentration in mcg/mL, and the x-axis shows time in hours, ranging from 0 to 70 hours. The graph includes shaded error bands representing ±2 standard deviations for both dosages.*

FDA Label Image

Metabolites (Metabolites)

A data table listing various metabolites and their relative percentages of dose for Nabumetone, including unchanged nabumetone (not detectable), 6-methoxy-2-naphthylacetic acid (unchanged and conjugated), 6-hydroxy-2-naphthylacetic acid (unchanged and conjugated), and other conjugates along with unidentified minor metabolites totaling 73% of the dose.*

FDA Label Image

Rx1 (Rx1)

A data table listing generic names of nonsteroidal anti-inflammatory drugs (NSAIDs) alongside their corresponding trade names. Examples include Celecoxib with Celebrex, Diclofenac with Cataflam and Voltaren, and Ibuprofen with Motrin and Vicoprofen (combined with hydrocodone).*

FDA Label Image

Rx2 (Rx2)

A data table showing a list of nonsteroidal anti-inflammatory drugs (NSAIDs) along with their corresponding brand names. Examples include Meloxicam (Mobic), Nabumetone (Relafen), Naproxen (Naprosyn, Anaprox, Anaprox DS, EC-Naproxyn, Naprelan, Naprapac co-packaged with lansoprazole), Oxaprozin (Daypro), Piroxicam (Feldene), Sulindac (Clinoril), and Tolmetin (Tolectin, Tolectin DS, Tolectin 600).*

FDA Label Image

Sse (Sse)

A drug side effects warning panel for Nabumetone listing serious side effects such as heart attack, stroke, high blood pressure, kidney problems, bleeding and ulcers, anemia, life-threatening skin and allergic reactions, liver problems, and asthma attacks. Other side effects include stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness.*

FDA Label Image

Structure (Structure)

Chemical structure of Nabumetone, displaying its molecular formula C15H16O2 and molecular weight of 228.3.*

FDA Label Image

Table1 (Table1)

Data table showing mean pharmacokinetic parameters of Nabumetone active metabolite (6MNA) at steady state following oral administration of 1,000 mg or 2,000 mg doses. Parameters include Tmax, half-life (t1/2), clearance (CLss/F), and volume of distribution (Vdss/F) for young adults and elderly groups with sample sizes indicated.*

FDA Label Image

Table2 (Table2)

A data table titled 'Table 2. Clinical Double-Blinded and Open-Labelled Trials of nabumetone in Osteoarthritis and Rheumatoid Arthritis' listing doses of Nabumetone (500 mg, 1,000 mg, 1,500 mg, 2,000 mg) alongside the number of patients with osteoarthritis (OA) and rheumatoid arthritis (RA) at each dose. The table also includes mean/mode duration of treatment in years for OA and RA patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.